Candel Therapeutics, Inc. 8-K

What Happened
Candel Therapeutics, Inc. announced an underwritten public offering of 18,348,624 shares of its common stock at $5.45 per share, pursuant to an underwriting agreement with Citigroup, Cantor Fitzgerald and Stifel as representatives. The company granted the underwriters a 30‑day option to purchase up to an additional 2,752,293 shares at the same price. The offering was made from a shelf registration on Form S-3 and was expected to close on or about February 23, 2026. Goodwin Procter LLP provided a legal opinion on the validity of the shares.

Key Details

• Shares offered: 18,348,624 common shares at $5.45 per share (the “Firm Shares”).
• Option: Underwriters may buy up to 2,752,293 additional shares within 30 days (the “Optional Shares”).
• Estimated net proceeds: approximately $93.5 million (or about $107.6 million if the option is fully exercised).
• Intended use of proceeds: launch readiness, medical affairs, pre-commercial and commercial activities for CAN-2409 in early localized prostate cancer; ongoing development of a Phase 3 trial for CAN-2409 in non-small cell lung cancer; and general corporate purposes.
• Cash runway: Company expects proceeds (assuming $93.5M) to fund operations into the first quarter of 2028, but notes this estimate could prove wrong.

Why It Matters
This equity raise provides Candel with fresh capital to advance its lead program CAN-2409 toward commercialization and continue a Phase 3 trial, reducing near-term financing pressure. For investors, the transaction dilutes existing shareholders but strengthens the company’s cash position with an immediate infusion expected to extend the company’s operating runway into early 2028 (based on current assumptions).